Theravance Biopharma
TBPH
#6135
Rank
$0.43 B
Marketcap
Cayman Islands
Country
$8.99
Share price
-1.43%
Change (1 day)
-18.35%
Change (1 year)
Categories
P/S ratio for Theravance Biopharma (TBPH)
P/S ratio as of April 2024 (TTM): 7.60
According to Theravance Biopharma 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 7.6023. At the end of 2023 the company had a P/S ratio of 9.75.
P/S ratio history for Theravance Biopharma from 2014 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 9.75 | -33.78% |
| 2022 | 14.7 | -0.02% |
| 2021 | 14.7 | -7.45% |
| 2020 | 15.9 | -20.88% |
| 2019 | 20.1 | -14.81% |
| 2018 | 23.6 | -75.93% |
| 2017 | 98.1 | 188.12% |
| 2016 | 34.0 | 130.35% |
| 2015 | 14.8 | -64.07% |
| 2014 | 41.1 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Corcept Therapeutics
CORT | 5.03 | -33.83% | 🇺🇸 USA |
 Collegium Pharmaceutical
COLL | 2.12 | -72.14% | 🇺🇸 USA |
 Catalyst Pharmaceuticals CPRX | 4.51 | -40.63% | 🇺🇸 USA |
 Catalent CTLT | 2.49 | -67.30% | 🇺🇸 USA |